The US Food and Drug Administration (FDA) approval – the first for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma – was based on a randomized, open-label trial, of 605 patients. The endpoint was to determine if the nivolumab-ipilimumab combo improved overall survival compared to chemotherapy.
The report is based on data collected from Medscape’s Physician Compensation Report 2020 in February 2020, representing responses from more than 17,000 physicians in more than 30 specialties. The slideshow paints an interesting picture considering the financial landscape for many physicians has changed due to COVID-19’s impact on medical practices.
In this Cleveland Clinic article, an internal medicine specialist discusses the different levels of COVID-19 infection risk in delivery, patio dining, and delivery for those that want food from a restaurant. The basics are covered, including wearing a mask to protect your server, but the article also discusses the attention that should be paid to […]